Pharmacopsychiatry
December 11, 2009
Georgios Paslakis, Morin Gilles, Andreas Meyer‐Lindenberg et al.
66 citations
We intended to assess safety, response to treatment and time to response of 1.25 mg/kg oral S-ketamine as add-on to standard antidepressants in four depressed patients. Two patients with melancholic depression responded early and stayed in remission, while two patients with distinct somatic symptoms, chronicity or atypical features did not respond. The limited number of patients does not allow...
Psychological Medicine
December 9, 2009
Jiřı́ Horáček, Martin Brunovský, Tomáš Novák et al.
42 citations
BACKGROUND: Theta cordance is a novel quantitative electroencephalography (QEEG) measure that correlates with cerebral perfusion. A series of clinical studies has demonstrated that the prefrontal theta cordance value decreases after 1 week of treatment in responders to antidepressants and that this effect precedes clinical improvement. Ketamine, a non-competitive antagonist of...
Bulletin of the Chemical Society of Japan
December 1, 2009
Takeshi Yokoyama, Reiko Yokoyama, Satoshi Nomura et al.
15 citations
Abstract The stereocenter in the intermediate alcohol (86% ee), created by enantioselective oxazaborolidinone-promoted aldol reaction, was transferred to the stereocenter in the cyclohexanone ring, necessary for (S)-ketamine, via allyl cyanate-to-isocyanate rearrangement. The second asymmetric synthesis of (S)-ketamine has been achieved (87% ee).
European Journal of Pain
November 8, 2009
Nora M. Hagelberg, Marko A. Peltoniemi, Teijo I. Saari et al.
55 citations
BACKGROUND: Oral ketamine is used as an adjuvant in the treatment of refractory neuropathic and cancer-related pain. Drug interactions may alter the analgesic or other effects of ketamine. AIM AND METHODS: The aim of the study was to investigate the effect of cytochrome P450 3A enzyme inhibition with clarithromycin on the pharmacokinetics and pharmacodynamics of oral S-ketamine in a randomized...
Anesthesiology
September 18, 2009
Marnix J. Sigtermans, Albert Dahan, René A. G. Mooren et al.
152 citations
BACKGROUND: Low-dose ketamine behaves as an analgesic in the treatment of acute and chronic pain. To further understand ketamine's therapeutic profile, the authors performed a population pharmacokinetic-pharmacodynamic analysis of the S(+)-ketamine analgesic and nonanalgesic effects in healthy volunteers. METHODS: Ten men and ten women received a 2-h S(+)-ketamine infusion. The infusion was...
The Journal of Clinical Psychiatry
September 8, 2009
Rodrigo Machado‐Vieira, Peixiong Yuan, Nancy E. Brutsché et al.
154 citations
OBJECTIVE: A model has been proposed to explain the pathophysiology of mood disorders based on decreased neurotrophin levels during mood episodes; treatment with antidepressants and mood stabilizers is associated with clinical improvement. This study investigated whether changes in brain-derived neurotrophic factor (BDNF) levels are associated with the initial antidepressant effects of...
Revista Brasileira de Psiquiatria
September 2009
Lara C Assis, Gislaine T Rezin, Clarissa M Comim et al.
Clinical findings suggest that ketamine may be used for the treatment of major depression. The present study aimed to compare behavioral effects and brain Creatine kinase activity in specific brain regions after administration of ketamine and imipramine in rats. Rats were acutely given ketamine or imipramine and antidepressant-like activity was assessed by the forced swimming test; Creatine...
Brain Research Bulletin
August 14, 2009
Gislaine T Rezin, Cinara L Gonçalves, Juliana F Daufenbach et al.
Modulation and dysfunction of the glutamatergic system seems to be involved in depression. Recently a renewed interest in the glutamatergic system as a treatment option for major depression emerged by the finding that the glutamate N-methyl-D-aspartate (NMDA) antagonist ketamine leads to a rapid improvement of depressive symptoms. Several works support the hypothesis that metabolism impairment...
Biological Psychiatry
July 9, 2009
R. Price, Matthew K. Nock, D. Charney et al.
Background Intravenous ketamine has shown rapid antidepressant effects in early trials, making it a potentially attractive candidate for depressed patients at imminent risk of suicide. The Implicit Association Test (IAT), a performance-based measure of association between two concepts, may have utility in suicide assessment. Methods Twenty-six patients with treatment-resistant depression were...
Neuroscience
June 30, 2009
E Engin, D Treit, C T Dickson
Ketamine, a dissociative anesthetic agent, appears to have rapid antidepressant effects at sub-anesthetic doses in clinically depressed patients. Although promising, these results need to be replicated in double-blind placebo-controlled studies, a strategy thwarted by the psychoactive effects of ketamine, which are obvious to both patients and clinicians. Alternatively, demonstrations of the...
Pharmacology & Therapeutics
May 3, 2009
Rodrigo Machado‐Vieira, Giacomo Salvadore, Nancy Diazgranados et al.
Existing treatments for major depressive disorder (MDD) usually take weeks to months to achieve their antidepressant effects, and a significant number of patients do not have adequate improvement even after months of treatment. In addition, increased risk of suicide attempts is a major public health concern during the first month of standard antidepressant therapy. Thus, improved therapeutics...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
April 30, 2009
Lêda S B Garcia, Clarissa M Comim, Samira S Valvassori et al.
Several studies have supported the idea that ionotropic glutamate N-methyl-d-aspartate receptor (NMDA) is an important player in the etiology of psychopathologies, such as anxiety disorders and major depression. Additionally, studies have shown that ketamine induces antidepressant effects in humans as well as in rodents subjected to animal models of depression. In this context, the present...
The FASEB Journal
April 1, 2009
Helmut B Gottlieb, Lisa Ji, JT Cunningham
One of active ingredients of Salvia divinorum , Salvinorin A (Sal A), has been shown to be a kappa opioid receptor agonist. The activation of central kappa opioid systems markedly affects renal function (water diuresis) in a manner that is different from any clinically used diuretic to date. The cardiovascular and renal effects produced by central administration of Salvinorin A are yet to be...
Journal of Psychopharmacology
March 20, 2009
Jörg Daumann, Daniel Wagner, Karsten Heekeren et al.
62 citations
Deficits in attentional functions belong to the core cognitive symptoms in schizophrenic patients. Alertness is a nonselective attention component that refers to a state of general readiness that improves stimulus processing and response initiation. The main goal of the present study was to investigate cerebral correlates of alertness in the human 5HT(2A) agonist and N-methyl-D-aspartic acid...
The International Journal of Neuropsychopharmacology
March 17, 2009
Sanjay J. Mathew, James W. Murrough, Marije Aan Het Rot et al.
295 citations
The N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine may have rapid, albeit transient, antidepressant properties. This study in patients with treatment-resistant major depression (TRD) aimed to (1) replicate the acute efficacy of single-dose intravenous (i.v.) ketamine; (2) test the efficacy of the glutamate-modulating agent riluzole in preventing post-ketamine relapse; and...
Psychopharmacology
March 1, 2009
Mark Blagrove, Celia J. A. Morgan, Helen Valerie Curran et al.
Ketamine is an N-methyl-D: -aspartate (NMDA) receptor antagonist with psychotogenic effects and for which there are diverse reports of whether pleasant or unpleasant dreams result during anaesthesia, post-operatively or after sub-anaesthetic use. To assess in healthy volunteers the incidence of unpleasant dreams over the three nights after receiving a sub-anaesthetic dose of ketamine, in...
Biological Psychiatry
February 15, 2009
Giacomo Salvadore, Brian R Cornwell, Veronica Colon-Rosario et al.
Most patients with major depressive disorder (MDD) experience a period of lengthy trial and error when trying to find optimal antidepressant treatment; identifying biomarkers that could predict response to antidepressant treatment would be of enormous benefit. We tested the hypothesis that pretreatment anterior cingulate cortex (ACC) activity could be a putative biomarker of rapid...
Frontiers in Systems Neuroscience
2009
Michael C. Quirk, Dara L Sosulski, Claudia E Feierstein et al.
Orbitofrontal cortex (OFC) is a region of prefrontal cortex implicated in the motivational control of behavior and in related abnormalities seen in psychosis and depression. It has been hypothesized that a critical mechanism in these disorders is the dysfunction of GABAergic interneurons that normally regulate prefrontal information processing. Here, we studied a subclass of interneurons...
cIRcle (University of British Columbia)
2009
Darrell Leong
The dissociative anaesthetic, ketamine, is commonly known as a NMDA receptor channel blocker. However, additional mechanisms of action probably contribute to its various clinical effects. We asked if ketamine influences transmission via AMPA/kainate glutamate receptor channels. Using whole cell patch clamp techniques in brain slices we recorded excitatory postsynaptic potentials, evoked by...
The World Journal of Biological Psychiatry
2009
Robert Paul, Nadine Schaaff, Frank Padberg et al.
Recent studies with intravenous infusion of the NMDA receptor antagonist ketamine showed robust and rapid antidepressant effects within hours after treatment. Ketamine is a racemic mixture consisting of two enantiomers, R- and S-ketamine. In contrast to ketamine, S-ketamine is reported to be less prone to psychomimetic side effects, such as derealisation and hallucinations. In this report we...